✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCAgingSafety Dr. Caplan’s Take “The emerging evidence on cannabinoids and hepatic steatosis is clinically meaningful...
Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchCBDHempAgingSafety Why This Matters Clinicians treating patients with non-alcoholic fatty liver disease or metabolic dysfunction-associated...
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchCBDSafety Why This Matters This finding is clinically significant because non-alcoholic fatty liver disease affects...
Daily Digest: Last 24 Hours: Cannabinoids and Liver Disease Lead a Busy News Cycle — March 07, 2026
Last 24 Hours March 07, 2026 — 52 articles reviewed This cycle was dominated by widespread coverage of preclinical research showing cannabinoids may combat fatty liver disease, alongside a cluster of state-level...
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com
WHY IT MATTERS: Patients managing metabolic syndrome, obesity, or early-stage fatty liver disease may want to discuss cannabinoid-based options with their physician as this area of research continues to develop. CLINICAL OVERVIEW: Preclinical and emerging clinical research suggests that certain cannabinoids, particularly CBD and to some extent THC, may help reduce hepatic fat accumulation and inflammation associated with metabolic-associated steatotic liver disease, formerly known as non-alcoholic fatty liver disease. These compounds appear to interact with the endocannabinoid system’s CB1 and CB2 receptors in hepatic tissue, with CB2 activation generally showing protective anti-inflammatory effects while CB1 activation may carry more complex metabolic implications.
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
WHY IT MATTERS: For the millions of patients with fatty liver disease who have limited pharmacological options, cannabinoid-based therapies could represent a meaningful new direction in treatment if ongoing clinical trials confirm these early findings. CLINICAL OVERVIEW: Emerging research suggests that cannabinoids, including both THC and CBD, may play a protective role against the development and progression of non-alcoholic fatty liver disease (NAFLD) by modulating hepatic inflammation, lipid metabolism, and fibrotic pathways through the endocannabinoid system. The liver expresses both CB1 and CB2 receptors, and while CB1 activation has historically been associated with pro-steatotic effects, selective CB2 stimulation appears to confer anti-inflammatory and antifibrotic benefits.
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCAgingSafety Dr. Caplan’s Take “What we’re seeing with cannabinoids and hepatic steatosis is a genuine...
Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchCBDHempSafety Why This Matters This research suggesting CBD and CBG may reduce hepatic steatosis and...
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial
IGC Pharma has added Visionary Investigators Network as a clinical site to its Phase 2 CALMA trial, which is evaluating a cannabinoid-based therapy for the management of agitation in Alzheimer’s disease. Expansion of enrollment sites is a standard step in Phase 2 trials to improve recruitment and support the generation of rigorous efficacy and safety data.
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurologyAgingSafety Why This Matters Clinicians can provide more nuanced counseling to older adult patients about...